Ben Venue Laboratories Enters Consent Decree
Ben Venue Laboratories has entered into a consent decree with FDA over violations of cGMP.
GSK Announces Joint Venture for Pediatric Vaccine
GlaxoSmithKline has formed a joint venture with Indian vaccines company Biological E to research and develop a six-in-one combination pediatric vaccine to help protect children in India and other developing countries from certain infectious diseases.
Actavis Unveils Long-Term Growth Strategy
Actavis unveiled its long-term growth strategy this week and officially re-introduced itself under the Actavis name following the EUR 4.25-billion ($5.4 billion) acquisition of the Actavis Group by Watson Pharmaceuticals in 2012.
AstraZeneca and Ceram Sign R&D Agreement
AstraZeneca and Ceram Research, a materials development company based in the UK, have signed an agreement whereby Ceram will develop its inorganic-based controlled release technology in a feasibility study for delivering select AstraZeneca compounds.
Allergan to Acquire MAP Pharmaceuticals
Allergan and MAP Pharmaceuticals have entered into a definite merger agreement under which Allergan will purchase all of MAP’s outstanding shares for the price of $25.00 per share.
UN pact Scuttles Anti-Vaccine Provision
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world.
EMA and FDA on Process Validation
Siegfried Schmitt, a principal consultant with PAREXEL, discusses the EMA's guideline on process validation and how it compares with FDA's process validaton guidance.
| 
